

Long COVID: Further Advances in Our Understanding of the Role of Specific Chemokines (CCR5, CCR6, CCR9, and CCL3) in Pediatrics

Hamidreza Farhadirad¹, Nasir Arefinia^{2*}, Zohreh-Al-Sadat Ghoreshi³, Fateme Sadeghzade¹

¹Student Research Committee Jiroft University of Medical Sciences Jiroft Iran ²Bio Environmental Health Hazard Research Center, Jiroft University of Medical Sciences, Jiroft, Iran ³School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran

ABSTRACT

Introduction: ARS-CoV-2 infection (COVID-19) is a major pandemic that has

caused significant mortality and morbidity worldwide. About 80% of patients

had mild or moderate disease, and 5% of patients with severe disease

developed severe disease. Long COVID-19, also known as post-COVID-19

syndrome, is a condition in which individuals continue to experience symptoms for weeks or months after recovering from COVID-19. There is a lack of sufficient data on the risk factors for post-COVID-19 sequelae in

OPEN ACCESS

*Corresponding Author: Environmental Health Bio Hazard Research Center, Jiroft University of Medical Sciences. Jiroft, Iran

> children. This study aimed to evaluate the long-term effects of severe COVID-19 on promotor methylation and expression genes, including CCR5, CCR6, CCR9, and CCL3 in children. Methods and Materials: Clinical data and blood samples from 94 long COVID patients and 25 healthy subjects were collected. Promotor methylation and mRNA expression of CCR5, CCR6, CCR9, and CCL3 genes in these patients and PCR assay.

Citation: Farhadirad H, Arefinia N, Ghoreshi ZAS, Sadeghzade F. The Long COVID: Further Advances in Our Understanding of the Role of Specific Chemokines (CCR5, CCR6, CCR9 and CCL3) in Pediatrics. Iranian biomedical journal. Supplementary (12-2024): 332.

control group were assessed through methylation-specific PCR and real-time **Results:** Our result indicated that promotors of CCR5 (p = 0.01) and CCL3 (p =0.006) in convalescence COVID-19 children were hyper-methylated compared to the healthy control group. Subsequently, CCR5 and CCL3 transcripts decreased compared to the control group (p = 0.01). In addition, CCL3 transcript in children with convalescent COVID-19 decreased compared to the control group (p = 0.008). However, we did not observe any significant modification in the transcript levels of CCR6 (p = 0.7) and CCR9 (p = 0.46) in children with convalescent COVID-19 compared to all the control groups.

Conclusion and Discussion: The CCR5 and CCL3 promoter region DNA methylation and the subsequent decrease in the expression of these genes were possibly correlated with long-term COVID-19 occurrence in children. Our study revealed additional data on the SARS-CoV-2-mediated inflammatory response.

Keywords: CCR5 receptor antagonists, Chemokine CCL3, Methylation

